title: Androgen receptor activation: a prospective therapeutic target for bladder cancer?
abstract: Patients with non-muscle-invasive or muscle-invasive bladder cancer undergoing surgery and currently available conventional therapy remain having a high risk of tumor recurrence or progression, respectively. Novel targeted molecular therapy is therefore expected to improve patient outcomes. Meanwhile, substantially higher incidence of bladder cancer in men has prompted research on androgen-mediated androgen receptor (AR) signaling in this malignancy. Indeed, preclinical evidence has suggested that AR signaling plays an important role in urothelial carcinogenesis and tumor outgrowth as well as resistance to some of the currently available conventional non-surgical therapies. Areas covered: We summarize and discuss available data suggesting the involvement of AR and its potential downstream targets in the development and progression of bladder cancer. Associations between AR signaling and sensitivity to cisplatin/doxorubicin or bacillus Calmette-Guérin treatment are also reviewed. Expert opinion: AR activation is likely to correlate with the promotion of urothelial carcinogenesis and cancer outgrowth as well as resistance to conventional therapies. Molecular therapy targeting the AR may thus provide effective chemopreventive and therapeutic approaches for urothelial cancer. Accordingly, bladder cancer can now be considered as an endocrine-related neoplasm. Clinical application of various anti-AR therapies available for AR-dependent prostate cancer to bladder cancer patients is anticipated.
authors.affiliation: a Department of Pathology and Laboratory Medicine , University of Rochester Medical Center , Rochester , NY , USA.|b Wilmot Cancer Institute , University of Rochester Medical Center , Rochester , NY , USA.
authors.forename: Taichi
authors.initials: T
authors.lastname: Mizushima
authors.affiliation: a Department of Pathology and Laboratory Medicine , University of Rochester Medical Center , Rochester , NY , USA.
authors.forename: Kathleen A
authors.initials: KA
authors.lastname: Tirador
authors.affiliation: a Department of Pathology and Laboratory Medicine , University of Rochester Medical Center , Rochester , NY , USA.|b Wilmot Cancer Institute , University of Rochester Medical Center , Rochester , NY , USA.|c Department of Urology , University of Rochester Medical Center , Rochester , NY , USA.
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Miyamoto
mesh_terms: D000728:Androgens / Q000378:metabolism; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D018450:Disease Progression; D006801:Humans; D008297:Male; D058990:Molecular Targeted Therapy; D009361:Neoplasm Invasiveness; D009364:Neoplasm Recurrence, Local; D011944:Receptors, Androgen / Q000378:metabolism*; D015398:Signal Transduction; D001749:Urinary Bladder Neoplasms / Q000473:pathology / Q000628:therapy*
chemical_list: D000728:Androgens; D000970:Antineoplastic Agents; D011944:Receptors, Androgen
keywords: Androgen; androgen receptor; bladder; carcinogenesis; tumor progression; urothelial cancer